Therapeutic efficacy of a novel membrane-targeted complement regulator in antigen-induced arthritis in the rat

Arthritis and Rheumatism

Volumn 43, Issue 11, 2000, Pages 2590-2597

  Linton, Stuart M ^a   Williams, Anwen S ^a   Dodd, Ian ^b   Smith, Richard ^b   Williams, Bryan D ^a   Paul Morgan, B ^c  

^a UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^b AdProTech plc   (United Kingdom)

^c CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; APT 070; APT 898; COMPLEMENT INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; ARTICLE; COMPLEMENT ACTIVATION; CONTROLLED STUDY; DRUG EFFICACY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SYNOVIUM;

ANIMALS; ANTIGENS; ARTHRITIS, EXPERIMENTAL; COMPLEMENT INACTIVATOR PROTEINS; KNEE JOINT; MALE; RATS; RATS, INBRED LEW;

EID: 0033758883     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(200011)43:11<2590::AID-ANR29>3.0.CO;2-R     Document Type: Article

References (40)

1. Physiology and pathophysiology of complement: Progress and trends
2. Correlation between levels of breakdown products of C3, C4, and properdin factor B in synovial fluids from patients with rheumatoid arthritis
3. Terminal complement complexes and C1/C1 inhibitor complexes in rheumatoid arthritis and other arthritic conditions
4. Synovial fluid levels of complement SC5b-9 and fragment Bb are elevated in patients with rheumatoid arthritis
5. Complement activation in rheumatoid arthritis evaluated by C3dg and the terminal complement complex
6. Membrane attack complex of complement in rheumatoid synovial tissue demonstrated by immunofluorescent microscopy
7. Immunohistochemical determination of complement activation in joint tissues of patients with rheumatoid arthritis and osteoarthritis using neo-antigen specific monoclonal antibodies
8. In vivo and in vitro evidence of cell recovery from complement attack in rheumatoid synovium
9. Stimulation of human rheumatoid synovial cell by non-lethal complement membrane attack?
10. Interaction of the terminal complement components C5b-9 with synovial fibroblasts-binding to the membrane surface leads to increased levels in collagenase-specific messenger RNA
11. Native type II collagen-induced arthritis in the rat: The effect of complement depletion by cobra venom factor
12. Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease
13. Local therapy with soluble complement receptor 1 (sCR1) suppresses inflammation in rat mono-articular arthritis
14. Soluble complementreceptor 1 (sCR1) inhibits the development and progression of rat collagen-induced arthritis
15. Overexpression in Escherichia coli, folding, purification and characterization of the first three short consensus repeat modules of human complement receptor type 1
16. Cell surface engineering using a complement regulatory molecule modified with a synthetic myristoyl-electrostatic switch derivative
17. Liposomal clodronate eliminates synovial macrophages, reduces inflammation and ameliorates joint destruction in antigen-induced arthritis
18. Structure-activity relationships within the N-terminal short consensus repeats (SCR) of human CR1 (C3b/C4b receptor, CD35): SCR 3 plays a critical role in inhibition of the classical and alternative pathways of complement activation
19. Immunofluorescent localization of the third and fourth component of complement in synovial tissue from patients with rheumatoid arthritis
20. The complement system in rheumatoid synovitis. II. Intracytoplasmic inclusions of immunoglobulins and complement
21. Identification of immunoglobulins and complement in rheumatoid articular collagenous tissues
22. Rheumatoid arthritis: Biosynthesis of complement proteins by synovial tissues
23. Gene expression (collagenase, tissue inhibitor of metalloproteinases, complement, and HLA-DR) in rheumatoid arthritis and osteoarthritis synovium: Quantitative analysis and effect of intraarticular corticosteroids
24. Complement components C1q, C1r/C1s, and C1INH in rheumatoid arthritis: Correlation of in situ hybridization and Northern blot results with function and protein concentration in synovium and primary cell cultures
25. Extrahepatic complement biosynthesis: Where, when and why?
26. Expression of decay-accelerating factor is reduced on hyperplastic synovial lining cells in rheumatoid synovitis
27. Complement in acute and chronic arthritides: Assessment of C3c, C9, and protectin (CD59) in synoviai membrane
28. The effects of functional suppression of a membrane-bound complement regulatory protein, CD59, in the synovial tissue in rats
29. The structure and function of the complement receptors CR1 (CD35) and CR2 (CD21)
30. Features of synovial membrane identified with monoclonal antibodies
31. The immunohistology of synovial lining cells in normal and in inflamed synovium
32. CR1, CD35 in synovial fluid from patients with inflammatory joint diseases
33. Soluble human complement receptor type h in vivo inhibitor of complement suppressing post-ischaemic myocardial inflammation and necrosis
34. Effects of complement inhibition with soluble complement receptor-1 on vascular injury and inflammation during renal allograft rejection in the rat
35. Endothelial targeting and enhanced anti-inflammatory effects of complement inhibitors possessing sialyl Lewis(x) moieties
36. Neuronal protection in stroke by an sLe(x)-glycosylated complement inhibitory protein
37. Rodent models of arthritis: Relevance for human disease
38. Anti TNF ameliorates joint disease in murine collagen-induced arthritis
39. The use of experimental arthritis in the rabbit for the development of antiarthritic drugs